Steven L Mcintire, MD
Neurology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 13
- 2 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
13 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Mcintire’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
13 of 13 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence G78670 · Current
Licensed to practise in California · since 1994 · expires 2027-05-31 · Harvard Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$44,613
Medicare paid this office $44,613 for 224 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 84 | $15,654 | $161 |
| Long return visit (40+ min) | 88 | $12,354 | $125 |
| New patient visit (60+ min) | 51 | $7,997 | $157 |
| New patient visit (60+ min) | 35 | $7,123 | $204 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 12 | $180 | $15 |
Who their Medicare patients are
224 Original Medicare patients in 2024. Average age 75 · Under 65 7% · 85 and older 15% · Women 51% · Also on Medicaid 25% · Health risk score 1.45. At or below the middle of the specialty; the typical neurology clinician is at 1.61.
Conditions among them: High blood pressure 70% · Coronary heart disease 25% · Diabetes 24% · Depression 24% · Chronic kidney disease 23% · Atrial fibrillation 22% · Stroke 17% · Heart failure 13% · Cancer 13% · Dementia 13% · COPD 11%.
The office billed $165,818, Medicare allowed $58,546 and paid $44,613; for 322 services of 8 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 224 | 322 | 75 | 1.45 | $165,818 | $44,613 |
| 2023 | 188 | 254 | 74 | 1.60 | $142,058 | $33,091 |
| 2022 | 185 | 255 | 74 | 1.50 | $128,318 | $32,961 |
| 2021 | 212 | 293 | 74 | 1.53 | $148,481 | $35,347 |
| 2020 | 208 | 294 | 73 | 1.52 | $119,410 | $26,515 |
| 2019 | 214 | 291 | 73 | 1.64 | $44,126 | $29,623 |
| 2018 | 204 | 272 | 72 | 1.44 | $42,735 | $27,677 |
| 2017 | 186 | 255 | 73 | 1.34 | $67,572 | $26,776 |
| 2016 | 187 | 231 | 72 | 1.42 | $75,557 | $23,384 |
| 2015 | 169 | 241 | 72 | 1.42 | $74,983 | $23,878 |
| 2014 | 182 | 279 | 71 | 1.42 | $84,656 | $26,773 |
| 2013 | 163 | 243 | 69 | 1.24 | $71,978 | $21,904 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 2 services
| Long return visit (40+ min) | 118 | $19,734 | $121 |
| New patient visit (60+ min) | 82 | $12,866 | $157 |
2022: 2 services
| Long return visit (40+ min) | 125 | $20,220 | $120 |
| New patient visit (60+ min) | 71 | $11,607 | $163 |
2021: 4 services
| Long return visit (40+ min) | 109 | $18,502 | $125 |
| New patient visit (60+ min) | 76 | $12,605 | $166 |
| Return visit (30+ min) | 13 | $739 | $57 |
| Short return visit | 15 | $556 | $33 |
2020: 7 services
| New patient visit (60+ min) | 75 | $11,008 | $147 |
| Long return visit (40+ min) | 64 | $7,438 | $98 |
| Return visit (30+ min) | 31 | $1,560 | $47 |
| Short return visit (20+ min) | 24 | $1,185 | $44 |
| Telephone medical discussion with physician, 21-30 minutes | 16 | $1,183 | $74 |
| Short return visit | 14 | $359 | $22 |
| Telehealth originating site facility fee | 14 | $298 | $21 |
2019: 4 services
| New patient visit (60+ min) | 122 | $17,382 | $142 |
| Return visit (30+ min) | 75 | $5,902 | $64 |
| Long return visit (40+ min) | 56 | $5,550 | $94 |
| Short return visit (20+ min) | 16 | $789 | $46 |
2018: 6 services
| New patient visit (60+ min) | 99 | $13,709 | $138 |
| Long return visit (40+ min) | 39 | $3,871 | $92 |
| New patient visit (60+ min) | 23 | $3,358 | $146 |
| Return visit (30+ min) | 52 | $3,327 | $57 |
| Return visit (30+ min) | 26 | $1,749 | $67 |
| Long return visit (40+ min) | 13 | $1,258 | $97 |
2017: 3 services
| New patient visit (60+ min) | 102 | $14,457 | $142 |
| Long return visit (40+ min) | 63 | $6,658 | $95 |
| Return visit (30+ min) | 66 | $5,547 | $68 |
2016: 4 services
| New patient visit (60+ min) | 108 | $14,413 | $133 |
| Long return visit (40+ min) | 54 | $4,806 | $89 |
| Return visit (30+ min) | 52 | $3,502 | $63 |
| Short return visit (20+ min) | 11 | $547 | $46 |
2015: 3 services
| New patient visit (60+ min) | 96 | $13,525 | $141 |
| Return visit (30+ min) | 55 | $5,049 | $64 |
| Long return visit (40+ min) | 43 | $4,512 | $87 |
2014: 3 services
| New patient visit (60+ min) | 106 | $15,012 | $142 |
| Return visit (30+ min) | 76 | $7,132 | $65 |
| Long return visit (40+ min) | 44 | $4,097 | $89 |
2013: 4 services
| New patient visit (60+ min) | 87 | $12,369 | $142 |
| Return visit (30+ min) | 68 | $4,993 | $59 |
| Long return visit (40+ min) | 27 | $2,469 | $91 |
| Short return visit (20+ min) | 23 | $1,009 | $39 |
Drugs they prescribed that Part D paid
$6,342
Pharmacies billed $6,342 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 267) in 2024. At or below the middle of the specialty; the typical neurology clinician is at 0%.
266 generic and fewer than 11 brand-name prescriptions · $6,342 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Gabapentin | 73 | $803 | $11 |
| Pregabalin | 23 | $587 | $26 |
| Nortriptyline | 25 | $569 | $23 |
| Carbidopa-Levodopa | 38 | $541 | $14 |
| Levetiracetam | 15 | $528 | $35 |
See all 6 drugs
| Gabapentin | 73 | $803 | $11 |
| Pregabalin | 23 | $587 | $26 |
| Nortriptyline | 25 | $569 | $23 |
| Carbidopa-Levodopa | 38 | $541 | $14 |
| Levetiracetam | 15 | $528 | $35 |
| Donepezil | 14 | $76 | $5 |
Year by year
| 2024 | 267 | 55 | 0% (0) | None | $6,342 |
| 2023 | 316 | 68 | 0% (0) | None | $19,674 |
| 2022 | 281 | 67 | 0% (0) | None | $27,855 |
| 2021 | 328 | 71 | 0% (0) | None | $56,139 |
| 2020 | 403 | 68 | 0% (0) | None | $23,132 |
| 2019 | 420 | 75 | 0% (0) | None | $22,359 |
| 2018 | 299 | 73 | 0% (0) | None | $18,070 |
| 2017 | 234 | 64 | 0% (0) | 6% | $16,000 |
| 2016 | 205 | 55 | 0% (0) | 8% | $13,556 |
| 2015 | 209 | 45 | 0% (0) | 10% | $10,226 |
| 2014 | 155 | 39 | 0% (0) | 12% | $10,677 |
| 2013 | 255 | 56 | 0% (0) | 11% | $13,442 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 7 drugs
| Gabapentin | 107 | $3,039 | $28 |
| Carbidopa-Levodopa | 40 | $1,584 | $40 |
| Duloxetine | 24 | $1,145 | $48 |
| Pregabalin | 13 | $770 | $59 |
| Nortriptyline | 27 | $316 | $12 |
| Donepezil | 16 | $225 | $14 |
| Levetiracetam | 12 | $90 | $7 |
2022: 8 drugs
| Duloxetine | 37 | $2,592 | $70 |
| Oxcarbazepine | 14 | $2,059 | $147 |
| Carbidopa-Levodopa | 31 | $1,430 | $46 |
| Gabapentin | 59 | $1,011 | $17 |
| Levetiracetam | 24 | $851 | $35 |
| Pregabalin | 24 | $678 | $28 |
| Nortriptyline | 23 | $290 | $13 |
| Donepezil | 13 | $67 | $5 |
2021: 7 drugs
| Carbidopa-Levodopa | 66 | $3,146 | $48 |
| Duloxetine | 30 | $2,276 | $76 |
| Levetiracetam | 36 | $2,238 | $62 |
| Gabapentin | 79 | $1,825 | $23 |
| Pregabalin | 13 | $340 | $26 |
| Nortriptyline | 22 | $261 | $12 |
| Donepezil | 16 | $93 | $6 |
2020: 7 drugs
| Carbidopa-Levodopa | 83 | $4,171 | $50 |
| Gabapentin | 138 | $1,777 | $13 |
| Levetiracetam | 33 | $1,411 | $43 |
| Pregabalin | 19 | $628 | $33 |
| Duloxetine | 38 | $582 | $15 |
| Nortriptyline | 29 | $472 | $16 |
| Donepezil Hcl Odt | 11 | $250 | $23 |
2019: 8 drugs
| Lyrica | 11 | $5,105 | $464 |
| Carbidopa-Levodopa | 116 | $4,599 | $40 |
| Gabapentin | 90 | $1,615 | $18 |
| Levetiracetam | 59 | $1,235 | $21 |
| Duloxetine | 21 | $808 | $38 |
| Donepezil | 24 | $637 | $27 |
| Nortriptyline | 26 | $360 | $14 |
| Donepezil Hcl Odt | 23 | $249 | $11 |
2018: 5 drugs
| Carbidopa-Levodopa | 73 | $3,621 | $50 |
| Levetiracetam | 45 | $2,071 | $46 |
| Gabapentin | 57 | $1,417 | $25 |
| Nortriptyline | 44 | $719 | $16 |
| Donepezil | 14 | $123 | $9 |
2017: 5 drugs
| Lyrica | 11 | $7,561 | $687 |
| Carbidopa-Levodopa | 58 | $2,622 | $45 |
| Levetiracetam | 28 | $1,811 | $65 |
| Gabapentin | 52 | $1,300 | $25 |
| Nortriptyline | 27 | $492 | $18 |
2016: 4 drugs
| Lyrica | 15 | $6,398 | $427 |
| Carbidopa-Levodopa | 43 | $1,651 | $38 |
| Gabapentin | 50 | $1,047 | $21 |
| Topiramate | 16 | $94 | $6 |
2015: 6 drugs
| Carbidopa-Levodopa | 26 | $1,081 | $42 |
| Amitriptyline | 13 | $785 | $60 |
| Gabapentin | 40 | $544 | $14 |
| Levetiracetam | 17 | $448 | $26 |
| Nortriptyline | 19 | $226 | $12 |
| Topiramate | 16 | $179 | $11 |
2014: 4 drugs
| Amitriptyline | 18 | $600 | $33 |
| Gabapentin | 27 | $573 | $21 |
| Nortriptyline | 22 | $496 | $23 |
| Sumatriptan | 13 | $280 | $22 |
2013: 6 drugs
| Lyrica | 14 | $5,556 | $397 |
| Gabapentin | 81 | $1,914 | $24 |
| Carbidopa-Levodopa | 25 | $844 | $34 |
| Baclofen | 26 | $789 | $30 |
| Nortriptyline | 32 | $607 | $19 |
| Amitriptyline | 25 | $262 | $10 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1619063989
- Licence
- CA G78670California G78670: Current · expires 2027-05-31
- Trained
- Harvard Medical School, 1992
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Neurology (2084N0400X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2006-10-05
- NPI last updated
- 2023-11-08
- NPI record certified
- 2023-11-08
This is when the NPI record was last certified, not a medical board exam.